Route of Delivery Modulates the Efficacy of Mesenchymal Stem Cell Therapy for Myocardial Infarction: A Meta-Analysis of Preclinical Studies and Clinical Trials

Overview

Journal Circ Res

Specialty Cardiology & Vascular Diseases

Date 2016 Dec 30

PMID 28031416

Citations 94

Authors

Anthony J Kanelidis

Courtney Premer

Juan Lopez

Wayne Balkan

Joshua M Hare

Affiliations

Soon will be listed here.

Abstract

Rationale: Accumulating data support a therapeutic role for mesenchymal stem cell (MSC) therapy; however, there is no consensus on the optimal route of delivery.

Objective: We tested the hypothesis that the route of MSC delivery influences the reduction in infarct size and improvement in left ventricular ejection fraction (LVEF).

Methods And Results: We performed a meta-analysis investigating the effect of MSC therapy in acute myocardial infarction (AMI) and chronic ischemic cardiomyopathy preclinical studies (58 studies; n=1165 mouse, rat, swine) which revealed a reduction in infarct size and improvement of LVEF in all animal models. Route of delivery was analyzed in AMI swine studies and clinical trials (6 clinical trials; n=334 patients). In AMI swine studies, transendocardial stem cell injection reduced infarct size (n=49, 9.4% reduction; 95% confidence interval, -15.9 to -3.0), whereas direct intramyocardial injection, intravenous infusion, and intracoronary infusion indicated no improvement. Similarly, transendocardial stem cell injection improved LVEF (n=65, 9.1% increase; 95% confidence interval, 3.7 to 14.5), as did direct intramyocardial injection and intravenous infusion, whereas intracoronary infusion demonstrated no improvement. In humans, changes of LVEF paralleled these results, with transendocardial stem cell injection improving LVEF (n=46, 7.0% increase; 95% confidence interval, 2.7 to 11.3), as did intravenous infusion, but again intracoronary infusion demonstrating no improvement.

Conclusions: MSC therapy improves cardiac function in animal models of both AMI and chronic ischemic cardiomyopathy. The route of delivery seems to play a role in modulating the efficacy of MSC therapy in AMI swine studies and clinical trials, suggesting the superiority of transendocardial stem cell injection because of its reduction in infarct size and improvement of LVEF, which has important implications for the design of future studies.

Citing Articles

Innovative therapeutic strategies for intrauterine adhesions: Role of umbilical cord mesenchymal stem cells in rat models.

Zhang M, Gao H, Zheng J, Du Y, Tian Y, Xiao Y Exp Ther Med. 2025; 29(3):55.

PMID: 39885907 PMC: 11775724. DOI: 10.3892/etm.2025.12805.

Rebuilding the myocardial microenvironment to enhance mesenchymal stem cells-mediated regeneration in ischemic heart disease.

Chu Q, Jiang X, Xiao Y Front Bioeng Biotechnol. 2024; 12:1468833.

PMID: 39372432 PMC: 11452912. DOI: 10.3389/fbioe.2024.1468833.

Application of Pro-angiogenic Biomaterials in Myocardial Infarction.

Liang T, Liu J, Liu F, Su X, Li X, Zeng J ACS Omega. 2024; 9(36):37505-37529.

PMID: 39281944 PMC: 11391569. DOI: 10.1021/acsomega.4c04682.

Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges.

Shan Y, Zhang M, Tao E, Wang J, Wei N, Lu Y Signal Transduct Target Ther. 2024; 9(1):242.

PMID: 39271680 PMC: 11399464. DOI: 10.1038/s41392-024-01936-8.

Navigating the Landscape of Coronary Microvascular Research: Trends, Triumphs, and Challenges Ahead.

Wang Y, Wang B, Ling H, Li Y, Fu S, Xu M Rev Cardiovasc Med. 2024; 25(8):288.

PMID: 39228508 PMC: 11366996. DOI: 10.31083/j.rcm2508288.

References

Hatzistergos K, Quevedo H, Oskouei B, Hu Q, Feigenbaum G, Margitich I . Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010; 107(7):913-22. PMC: 3408082. DOI: 10.1161/CIRCRESAHA.110.222703. View

Kelkar A, Butler J, Schelbert E, Greene S, Quyyumi A, Bonow R . Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells. J Am Coll Cardiol. 2015; 66(18):2038-2047. DOI: 10.1016/j.jacc.2015.09.010. View

Gao L, Pei X, Ding Q, Chen Y, Zhang N, Chen H . A critical challenge: dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction. Int J Cardiol. 2013; 168(4):3191-9. DOI: 10.1016/j.ijcard.2013.04.112. View

Sheng C, Zhou L, Hao J . Current stem cell delivery methods for myocardial repair. Biomed Res Int. 2013; 2013:547902. PMC: 3591183. DOI: 10.1155/2013/547902. View

Williams A, Suncion V, McCall F, Guerra D, Mather J, Zambrano J . Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. J Am Heart Assoc. 2013; 2(3):e000140. PMC: 3698774. DOI: 10.1161/JAHA.113.000140. View

Heldman A, DiFede D, Fishman J, Zambrano J, Trachtenberg B, Karantalis V . Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2013; 311(1):62-73. PMC: 4111133. DOI: 10.1001/jama.2013.282909. View

Hare J, Traverse J, Henry T, Dib N, Strumpf R, Schulman S . A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54(24):2277-86. PMC: 3580848. DOI: 10.1016/j.jacc.2009.06.055. View

Williams A, Hare J . Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011; 109(8):923-40. PMC: 3604746. DOI: 10.1161/CIRCRESAHA.111.243147. View

van der Spoel T, Gathier W, Koudstaal S, van Slochteren F, Of Lorkeers S, Sluijter J . Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction. J Cardiovasc Transl Res. 2015; 8(7):393-403. PMC: 4623074. DOI: 10.1007/s12265-015-9643-3. View

10.

Lee J, Lee S, Youn Y, Ahn M, Kim J, Yoo B . A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. J Korean Med Sci. 2014; 29(1):23-31. PMC: 3890472. DOI: 10.3346/jkms.2014.29.1.23. View

11.

Milani-Nejad N, Janssen P . Small and large animal models in cardiac contraction research: advantages and disadvantages. Pharmacol Ther. 2013; 141(3):235-49. PMC: 3947198. DOI: 10.1016/j.pharmthera.2013.10.007. View

12.

Hashemi S, Ghods S, Kolodgie F, Parcham-Azad K, Keane M, Hamamdzic D . A placebo controlled, dose-ranging, safety study of allogenic mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction. Eur Heart J. 2007; 29(2):251-9. DOI: 10.1093/eurheartj/ehm559. View

13.

van den Akker F, Deddens J, Doevendans P, Sluijter J . Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochim Biophys Acta. 2012; 1830(2):2449-58. DOI: 10.1016/j.bbagen.2012.08.026. View

14.

Golpanian S, Schulman I, Ebert R, Heldman A, DiFede D, Yang P . Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease. Stem Cells Transl Med. 2015; 5(2):186-91. PMC: 4729551. DOI: 10.5966/sctm.2015-0101. View

15.

Harding J, Roberts R, Mirochnitchenko O . Large animal models for stem cell therapy. Stem Cell Res Ther. 2013; 4(2):23. PMC: 3706788. DOI: 10.1186/scrt171. View

16.

Karantalis V, DiFede D, Gerstenblith G, Pham S, Symes J, Zambrano J . Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal.... Circ Res. 2014; 114(8):1302-10. PMC: 4104798. DOI: 10.1161/CIRCRESAHA.114.303180. View

17.

Kurtz A . Mesenchymal stem cell delivery routes and fate. Int J Stem Cells. 2014; 1(1):1-7. PMC: 4021770. DOI: 10.15283/ijsc.2008.1.1.1. View

18.

Wang X, Xi W, Wang F . The beneficial effects of intracoronary autologous bone marrow stem cell transfer as an adjunct to percutaneous coronary intervention in patients with acute myocardial infarction. Biotechnol Lett. 2014; 36(11):2163-8. DOI: 10.1007/s10529-014-1589-z. View

19.

Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y . Immunobiology of mesenchymal stem cells. Cell Death Differ. 2013; 21(2):216-25. PMC: 3890955. DOI: 10.1038/cdd.2013.158. View

20.

Amado L, Saliaris A, Schuleri K, John M, Xie J, Cattaneo S . Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A. 2005; 102(32):11474-9. PMC: 1183573. DOI: 10.1073/pnas.0504388102. View